Fox Chase Cancer Center

Site:	Fox Chase Cancer Center	Go to their website
Address:	333 Cottman Ave
City:	Philadelphia
State:	PA
Zip:	19111
Country:	USA

36 trials at this site

Phase [asc]	Trial	Trial Status	Site Status	Drug	NCT#
1	Phase 1 Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	Sunitinib + CP-751,871	NCT00729833
1	A Pilot Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5, Alone or In Combination with Imatinib Mesylate or Sunitinib Malate In Subjects with Advanced Gastrointestinal Stromal Tumors	Withdrawn	Closed	CS-1008 and Imatinib or Sunitinib
1	Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)	Completed	Closed	Imatinib and Nilotinib	NCT00135005
1	Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors	Ongoing, but not recruiting	Closed	BIIB022	NCT00555724
1	Safety Study of PLX108-01 in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 (PLX108-01)	NCT01004861
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
1	A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT02571036
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237
2	Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) (07060)	Terminated	Closed	Nilotinib	NCT00782834
2	A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing c-Kit Gene (Extension of US Phase II study, B2222)	Completed	Closed	Imatinib	NCT00237185
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
2	Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)	Terminated	Closed	Nilotinib and Imatinib	NCT01089595
2	A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)	Completed	Closed	STA-9090	NCT01039519
2	Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01068769
2	Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene	Completed	Closed	Crenolanib (CP-868,596)	NCT01243346
2	Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors	Completed	Closed	Imatinib + RAD001	NCT01275222
2	A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST	Completed	Closed	Imatinib + AT13387	NCT01294202
2	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors	Completed	Closed	Linsitinib (OSI-906)	NCT01560260
2	A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor	Completed	Closed	Ponatinib (Iclusig)	NCT01874665

Fox Chase Cancer Center

36 trials at this site

Page 1 of 2 | Next | Last